Total amount: € 0,00
HOW TO ORDER
A Journal on Endocrine System Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118
Minerva Endocrinologica 2017 Mar 14
Copyright © 2017 EDIZIONI MINERVA MEDICA
The anti-inflammatory protein kallistatin is associated with carotid intima media thickness in
women with polycystic ovary syndrome
Mehmet CALAN 1 ✉, Aslı GULER 2, Gokcen UNAL KOCABAS 1, Pınar ALARSLAN 3, Merve BICER 4, Cetin IMAMOGLU 5, Arif YUKSEL 6, Giray BOZKAYA 7, Oktay BILGIR 6
1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey; 2 Department of Family Physician, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey; 3 Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Ataturk Training and Research Hospital, Bozyaka, Izmir, Turkey; 4 Department of Obstetrics and Gynecology, Medical Park Hospital, Izmir, Turkey; 5 Department of Radiology, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey; 6 Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey; 7 Department of Biochemistry and Clinical Biochemistry, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey
BACKGROUND: Kallistatin is a secreted protein that acts as a tissue kallikrein inhibitor. It has antiinflammatory, antioxidant and vasoprotective properties. Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disease associated with low-grade chronic inflammation and multiple risk factors for cardiovascular diseases. The aims of this study were to ascertain whether circulating kallistatin levels are altered in women with PCOS, and whether there is an association between kallistatin and carotid intima media thickness (cIMT) as well as inflammatory markers high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α).
METHODS: This cross-sectional study included 75 women with PCOS and 75 age- and BMI-matched controls without PCOS. Circulating kallistatin and TNF-α levels were measured using ELISA. Metabolic and hormonal parameters, hs-CRP levels and cIMT were also determined. All subjects underwent the 2-h oral glucose tolerance test (2-h OGTT).
RESULTS: Circulating kallistatin levels were significantly elevated in women with PCOS compared to controls (6.31 ± 2.09 vs. 4.79 ± 2.26 ng/ml, P<0.001). Inflammatory markers hs-CRP and TNF-α were found to be elevated in women with PCOS. Kallistatin levels positively correlated with insulin, insulin resistance index (HOMA-IR), free androgen index, hs-CRP, TNF-α and cIMT in both PCOS and control groups. Kallistatin levels did not show correlation with BMI, blood pressure, fasting blood glucose, 2-h OGTT or HbA1C. Multiple linear regression analysis revealed that kallistatin is an independent predictor for cIMT (β = 0.131, 95% CI = 0.114 - 0.150, P = 0.019).
CONCLUSIONS: Kallistatin levels may provide useful information regarding cardiovascular risk in women with PCOS.
KEY WORDS: Polycystic ovary syndrome - Kallistatin - Carotid intima media thickness - Low-grade chronic inflammation